Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis

References

• Crotti C, Biggioggero M, Becciolini A, et al. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2019;17:1–9.
   Google Scholar
• Scott DL. Radiological progression in established rheumatoid arthritis. J Rheumatol Suppl. 2004;69:55–65.
   PubMedGoogle Scholar
• Noack M, Miossec P. Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol. 2017;39:365–383.
   PubMed Web of Science ®Google Scholar
• Moore BW, Perez VJ, Gehring M. Assay and regional distribution of a soluble protein characteristic of the nervous system. J Neurochem. 1968;15:265–272.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41:2104–2113.
   PubMed Web of Science ®Google Scholar
• Aghazadeh Y, Papadopoulos V. The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discov Today. 2016;21:278–287.
   PubMed Web of Science ®Google Scholar
• Carrier N, Marotta A, de Brum-Fernandes AJ, et al. Serum levels of 14-3-3eta protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther. 2016;18:37.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun W, Gao R, et al. The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology. 2013;52:1739–1747.
   PubMed Web of Science ®Google Scholar
• Cai Y, Jiang C, Zhu J, et al. miR-449a inhibits cell proliferation, migration, and inflammation by regulating high-mobility group box protein 1 and forms a mutual inhibition loop with Yin Yang 1 in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Res Ther. 2019;21:134–143.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–2581.
   PubMed Web of Science ®Google Scholar
• Kongpachith S, Lingampalli N, Ju CH, et al. Affinity maturation of the anti-citrullinated protein antibody paratope drives epitope spreading and polyreactivity in rheumatoid arthritis. Arthritis Rheumatol. 2019;71:507–517.
   PubMed Web of Science ®Google Scholar
• Boissier MC, Semerano L, Challal S, et al. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun. 2012;39:222–228.
   PubMed Web of Science ®Google Scholar
• Xu N, Zhao S, Xue H, et al. Associations of perceived social support and positive psychological resources with fatigue symptom in patients with rheumatoid arthritis. PLoS One. 2017;12:e173293.
   Web of Science ®Google Scholar
• Shovman O, Gilburd B, Watad A, et al. The diagnostic value of 14-3-3eta protein levels in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32:610–617.
   PubMed Web of Science ®Google Scholar
• Cecchinato V, D’Agostino G, Raeli L, et al. Redox-mediated mechanisms fuel monocyte responses to CXCL12/HMGB1 in active rheumatoid arthritis. Front Immunol. 2018;9:2118–2129.
   PubMed Web of Science ®Google Scholar
• Barouta G, Katsiari CG, Alexiou I, et al. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (less than 3 months duration) rheumatoid arthritis. Clin Rheumatol. 2017;36:885–894.
   PubMed Web of Science ®Google Scholar
• Kilani RT, Maksymowych WP, Aitken A, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007;34:1650–1657.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Boire G, van Schaardenburg D, et al. 14-3-3eta autoantibodies: diagnostic use in early rheumatoid arthritis. J Rheumatol. 2015;42:1587–1594.
   PubMed Web of Science ®Google Scholar
• Esalatmanesh K, Jamali R, Jamali A, et al. Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis. Rheumatol Int. 2012;32:3799–3805.
   PubMedGoogle Scholar
• Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122:1791–1802.
   PubMed Web of Science ®Google Scholar
• Guo HF, Liu SX, Zhang YJ, et al. High mobility group box 1 induces synoviocyte proliferation in rheumatoid arthritis by activating the signal transducer and activator transcription signal pathway. Clin Exp Med. 2011;11:65–74.
   PubMed Web of Science ®Google Scholar
• Alessandri C, Agmon-Levin N, Conti F, et al. Anti-mutated citrullinated vimentin antibodies in antiphospholipid syndrome: diagnostic value and relationship with clinical features. Immunol Res. 2017;65:524–531.
   PubMed Web of Science ®Google Scholar
• Zhu T, Feng L. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients. Int J Rheum Dis. 2013;16:157–161.
   PubMed Web of Science ®Google Scholar
• Gong X, Xu SQ, Wu Y, et al. Elevated serum 14-3-3eta protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol. 2017;36:2581–2587.
   PubMed Web of Science ®Google Scholar